Novel insight into the role of immunotherapy in gastrointestinal cancer (Review)

Liu,Yaran; Chen,Jiaqi; Xu,Yanjie; Sun,Qiang

doi:10.3892/mco.2022.2590

Novel insight into the role of immunotherapy in gastrointestinal cancer (Review)

Authors:
- Yaran Liu
- Jiaqi Chen
- Yanjie Xu
- Qiang Sun
View Affiliations

Affiliations: Institute of Medical Artificial Intelligence, Binzhou Medical College, Yantai, Shandong 264003, P.R. China, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China, Department of Oncology, Haining People's Hospital, Haining Branch, The First Affiliated Hospital of Zhejiang University, Jiaxing, Zhejiang 314001, P.R. China, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
Published online on: October 11, 2022 https://doi.org/10.3892/mco.2022.2590
Article Number: 157
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To date, great progress has been made in studying the immunology of cancer and the development of immunotherapies. Immunotherapy has become an effective clinical strategy for cancer treatment in courtesy of its unique features. It has been demonstrated to delay tumor progression, reduce tumor recurrence and metastasis, and even cure tumors through enhancing the immune response, stimulating tumor‑specific immunity and breaking immune tolerance. Several different immunotherapeutic approaches and methods are in the process of being developed, including the use of cytokines, immune checkpoint inhibitors, engineered T cells (such as T‑cell‑receptor T cells and chimeric antigen receptor T cells) and cancer vaccines. Digestive system neoplasms pose a serious threat to human health, including esophageal cancer, gastric cancer and colorectal cancer, and immunotherapy is considered to be a promising new avenue for the treatment of digestive system neoplasms. However, certain challenges remain in terms of the broad implementation of immunotherapies due to the incompletely understood mechanisms underlying tumorigenesis. Therefore, it is crucially important to understand both the various different types of immunotherapy and the immune landscapes in digestive system neoplasms in order to reduce the side effects associated with these therapies. The present review discusses existing and newly emerging immunotherapeutic methods that may be applied in the treatment of digestive system neoplasms and how their clinical efficacy may be enhanced.

View Figures

View References

1	Chen Q, Wang C, Chen G, Hu Q and Gu Z: Delivery strategies for immune checkpoint blockade. Adv Healthc Mater. 7(e1800424)2018.PubMed/NCBI View Article : Google Scholar
2	Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R and Vivier E: Harnessing innate immunity in cancer therapy. Nature. 574:45–56. 2019.PubMed/NCBI View Article : Google Scholar
3	Kakimi K, Karasaki T, Matsushita H and Sugie T: Advances in personalized cancer immunotherapy. Breast Cancer. 24:16–24. 2017.PubMed/NCBI View Article : Google Scholar
4	Zhang YY and Zhang ZM: The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 17:807–821. 2020.PubMed/NCBI View Article : Google Scholar
5	Abbott M and Ustoyev Y: Cancer and the immune system: The history and background of immunotherapy. Semin Oncol Nurs. 35(150923)2019.PubMed/NCBI View Article : Google Scholar
6	Chen Q, Chen MC and Liu Z: Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chem Soc Rev. 48:5506–5526. 2019.PubMed/NCBI View Article : Google Scholar
7	Murciano-Goroff YR, Warner AB and Wolchok JD: The future of cancer immunotherapy: Microenvironment-targeting combinations. Cell Res. 30:507–519. 2020.PubMed/NCBI View Article : Google Scholar
8	Tang S, Ning Q, Yang L, Mo Z and Tang S: Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 86(106700)2020.PubMed/NCBI View Article : Google Scholar
9	Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P and Deshmukh RR: Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci. 21(5009)2020.PubMed/NCBI View Article : Google Scholar
10	Kumar A, Swain CA and Shevde LA: Informing the new developments and future of cancer immunotherapy future of cancer immunotherapy. Cancer Metast Rev. 40:549–562. 2021.PubMed/NCBI View Article : Google Scholar
11	Finn OJ: A believer's overview of cancer immunosurveillance and immunotherapy. J Immunol. 200:385–391. 2018.PubMed/NCBI View Article : Google Scholar
12	Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. 2017.PubMed/NCBI View Article : Google Scholar
13	Helmy KY, Patel SA, Nahas GR and Rameshwar P: Cancer immunotherapy: Accomplishments to date and future promise. Ther Deliv. 4:1307–1320. 2013.PubMed/NCBI View Article : Google Scholar
14	Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A: Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707–723. 2017.PubMed/NCBI View Article : Google Scholar
15	Gubin MM and Vesely MD: Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res. 20:3917–3928. 2022.PubMed/NCBI View Article : Google Scholar
16	Kelly RJ: The emerging role of immunotherapy for esophageal cancer. Curr Opin Gastroenterol. 35:337–343. 2019.PubMed/NCBI View Article : Google Scholar
17	Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al: Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell. 35:238–255.e6. 2019.PubMed/NCBI View Article : Google Scholar
18	Hsu A, Mendelson L and Almhanna K: Immune checkpoint inhibitors in the treatment of gastrointestinal malignancies: A review of current and future therapies. R I Med J (2013). 103:33–37. 2020.PubMed/NCBI
19	Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W and Su D: Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 7:30772–30780. 2016.PubMed/NCBI View Article : Google Scholar
20	Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J and Wu C: B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI
21	Ostrand-Rosenberg S, Horn LA and Haile ST: The programmed death-1 immune-suppressive pathway: Barrier to antitumor immunity. J Immunol. 193:3835–3841. 2014.PubMed/NCBI View Article : Google Scholar
22	Pham F and Dalle S: Safety of pembrolizumab for resected stage III melanoma. Expert Opin Drug Saf. 19:1221–1227. 2020.PubMed/NCBI View Article : Google Scholar
23	Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4(e180013)2018.PubMed/NCBI View Article : Google Scholar
24	Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17:956–965. 2016.PubMed/NCBI View Article : Google Scholar
25	Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, et al: Increased Tim-3(+) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother. 67:1673–1683. 2018.PubMed/NCBI View Article : Google Scholar
26	Zhao Y, Yang W, Huang Y, Cui R, Li X and Li B: Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 47:721–734. 2018.PubMed/NCBI View Article : Google Scholar
27	Kojima T and Doi T: Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep. 19(33)2017.PubMed/NCBI View Article : Google Scholar
28	Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M and Doki Y: High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine. 32:5901–5907. 2014.PubMed/NCBI View Article : Google Scholar
29	Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, et al: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 12(84)2014.PubMed/NCBI View Article : Google Scholar
30	Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, et al: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 10(141)2012.PubMed/NCBI View Article : Google Scholar
31	Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y and Fujii H: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509. 2009.PubMed/NCBI View Article : Google Scholar
32	Alsina M, Moehler M and Lorenzen S: Immunotherapy of esophageal cancer: Current status, many trials and innovative strategies. Oncol Res Treat. 41:266–271. 2018.PubMed/NCBI View Article : Google Scholar
33	Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K and Itoh K: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res. 6:4663–4673. 2000.PubMed/NCBI
34	Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al: Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. 21:2268–2277. 2015.PubMed/NCBI View Article : Google Scholar
35	Schizas D, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Zhao M, Ajani JA, Psyrri A, Karamouzis MV and Liakako T: Immunotherapy for esophageal cancer: A 2019 update. Immunotherapy. 12:203–218. 2020.PubMed/NCBI View Article : Google Scholar
36	Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, Hawkins RE and Thistlethwaite FC: Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 16:1662–1672. 2010.PubMed/NCBI View Article : Google Scholar
37	De Mello RA, Lordick F, Muro K and Janjigian YY: Current and future aspects of immunotherapy for esophageal and gastric malignancies. Am Soc Clin Oncol Educ Book. 39:237–247. 2019.PubMed/NCBI View Article : Google Scholar
38	Le DT, Bendell JC, Calvo E, Kim JW, Ascierto PA, Ott PS, Bono P, Jaeger D, Evans TR, Braud FG, et al: Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. J Clin Oncol. 34(79157577)2016.
39	Kang YK, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yoshikawa T, et al: Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol 35: DOI:10.1200/JCO.2017.35.4_SUPPL.2, 2017.
40	de Guillebon E, Roussille P, Frouin E and Tougeron D: Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol. 7:95–101. 2015.PubMed/NCBI View Article : Google Scholar
41	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
42	Fuchs CS, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 25:197–206. 2022.PubMed/NCBI View Article : Google Scholar
43	Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al: Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6:1571–1580. 2020.PubMed/NCBI View Article : Google Scholar
44	Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al: Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 24:1449–1458. 2018.PubMed/NCBI View Article : Google Scholar
45	Chen Y, Guo ZQ, Shi CM, Zhou ZF, Ye YB and Chen Q: Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int J Clin Exp Med. 8:7728–7736. 2015.PubMed/NCBI
46	Yoneda A, Kuroki T and Eguchi S: Immunotherapeutic advances in gastric cancer. Surg Today. 51:1727–1735. 2021.PubMed/NCBI View Article : Google Scholar
47	Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, et al: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 41:1297–1304. 2012.PubMed/NCBI View Article : Google Scholar
48	Ishikawa H, Imano M, Shiraishi O, Yasuda A, Peng YF, Shinkai M, Yasuda T, Imamoto H and Shiozaki H: Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric. 17:173–180. 2014.PubMed/NCBI View Article : Google Scholar
49	Zhang GQ, Zhao H, Wu JY, Li JY, Yan X, Wang G, Wu LL, Zhang XG, Shao Y, Wang Y and Jiao SC: Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World J Gastroenterol. 21:2777–2785. 2015.PubMed/NCBI View Article : Google Scholar
50	Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, Zhao X, Wang Y, Wang Z, Han W and Chen L: Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 9:867–878. 2018.PubMed/NCBI View Article : Google Scholar
51	Xie J, Fu L and Jin L: Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathol Res Pract. 218(153322)2021.PubMed/NCBI View Article : Google Scholar
52	Johdi NA and Sukor NF: Colorectal cancer immunotherapy: Options and strategies. Front Immunol. 11(1624)2020.PubMed/NCBI View Article : Google Scholar
53	Marcus L, Lemery SJ, Keegan P and Pazdur R: FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 25:3753–3758. 2019.PubMed/NCBI View Article : Google Scholar
54	Ardolino L and Joshua A: Immune checkpoint inhibitors in malignancy. Aust Prescr. 42:62–67. 2019.PubMed/NCBI View Article : Google Scholar
55	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aguilar EA, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Anna Oncol. 27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
56	Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Eng J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar
57	Leoni G, D'Alise AM, Cotugno G, Langone F, Garzia I, De Lucia M, Fichera I, Vitale R, Bignone V, Tucci FG, et al: A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res. 80:3972–3982. 2020.PubMed/NCBI View Article : Google Scholar
58	Quiroga D, Lyerly HK and Morse MA: Deficient mismatch repair and the role of immunotherapy in metastatic colorectal cancer. Curr Treat Options Oncol. 17(41)2016.PubMed/NCBI View Article : Google Scholar
59	Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, et al: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet. 353:345–350. 1999.PubMed/NCBI View Article : Google Scholar
60	de Weger VA, Turksma AW, Voorham QJ, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB, van Tinteren H, et al: Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res. 18:882–889. 2012.PubMed/NCBI View Article : Google Scholar
61	Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 19:620–626. 2011.PubMed/NCBI View Article : Google Scholar
62	Pegram HJ, Park JH and Brentjens RJ: CD28z CARs and armored CARs. Cancer J. 20:127–133. 2014.PubMed/NCBI View Article : Google Scholar
63	Wang DK, Zuo Q, He QY and Li B: Targeted immunotherapies in gastrointestinal cancer: From molecular mechanisms to implications. Front Immunol. 12(705999)2021.PubMed/NCBI View Article : Google Scholar
64	Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, et al: FDA approval summary: Pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 27:4680–4684. 2021.PubMed/NCBI View Article : Google Scholar
65	Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.PubMed/NCBI View Article : Google Scholar
66	Saito M and Kono K: Landscape of EBV-positive gastric cancer. Gastric Cancer. 24:983–989. 2021.PubMed/NCBI View Article : Google Scholar
67	Li K, Zhang A, Li X, Zhang H and Zhao L: Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 1876(188615)2021.PubMed/NCBI View Article : Google Scholar
68	Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, et al: Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 36:3223–3230. 2018.PubMed/NCBI View Article : Google Scholar
69	Harpreet S, Christopher H, Jennifer M, et al: A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. J Clin Oncol. 32: 15_suppl(e14026-e14026)2014.